Henry M. Colecraft

This study demonstrates the use of divalent nanobodies to recruit NEDD4-2 E3 ligase to degrade ion channels, reducing their function with minimal off-target effects.

This study uses engineered deubiquitinases to investigate how different polyubiquitin linkages regulate KCNQ1 functional expression and trafficking, revealing distinct roles for each linkage type.

The paper identifies a novel CaV2.2 channel antagonist with broad antinociceptive effects and reduced side effects in pain models.